Fecal Incontinence — CPB 0611 | AETNA Coverage Update

Aetna modified CPB 0611 for fecal incontinence, effective February 27, 2026. Here's what billing teams need to know about coverage criteria, affected codes, and what Aetna now considers experimental.

Aetna, a CVS Health company, updated its fecal incontinence coverage policy under CPB 0611 Aetna system. This policy governs medical necessity for a wide range of diagnostic, conservative, and surgical interventions — from anorectal manometry through sacral nerve stimulation (CPT 64561, 64581) and the Acticon Neosphincter. If your practice treats fecal incontinence and bills Aetna, this update touches nearly every layer of your coding and documentation workflow.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Fecal Incontinence – CPB 0611
Policy Code	CPB 0611
Change Type	Modified
Effective Date	February 27, 2026
Impact Level	High
Specialties Affected	Colorectal surgery, gastroenterology, urology, general surgery, physical therapy, nutrition/dietetics
Key Action	Audit your documentation for the 3-month conservative treatment trial before billing any invasive procedure under CPB 0611

---

Aetna Fecal Incontinence Coverage Criteria and Medical Necessity Requirements 2026

Aetna's fecal incontinence coverage policy draws a hard line between conservative and invasive treatment. You cannot bill for surgery, neuromodulation, or artificial sphincter implantation without documented evidence of a failed conservative trial first.

The policy requires a 3-month trial of two or more traditional treatments before any invasive intervention is considered medically necessary. Those traditional treatments include biofeedback (CPT 90912, +90913), bowel training, defecation programs, diet modification, and pharmacotherapy. If your chart doesn't show this trial, Aetna will deny the claim.

Diagnostic tests covered under medical necessity:

#	Covered Indication Copy
1	Anorectal manometry (see Aetna CPB 0616)
2	Anorectal ultrasonography
3	Rectal sensory testing

These diagnostics do not require the 3-month conservative trial. Bill them with the appropriate ICD-10-CM code from the R15.x range (R15.0 through R15.9) to support medical necessity.

Invasive procedures covered when criteria are met:

Aetna defines "severe" fecal incontinence as involuntary loss of solid or liquid stool on a weekly or more frequent basis. That definition matters for prior authorization. If you're submitting a prior auth for sphincter repair, colostomy, the Acticon Neosphincter, or sacral nerve stimulation, document severity using that specific standard — not just a general diagnosis of incontinence.

Anal sphincter repair (CPT 46750, 46751, 46760, 46761) is covered for members with severe fecal incontinence who have failed, or cannot attempt, medical interventions such as biofeedback, dietary management, pharmacotherapy, or strengthening exercises.

Colostomy is covered for members with severe fecal incontinence who have failed medical interventions and surgical sphincter repair options, including post-anal repair, sphincteroplasty, or total pelvic floor repair.

The Acticon Neosphincter artificial bowel sphincter is covered for members 18 years of age or older with severe fecal incontinence — weekly or more frequent involuntary stool loss — who have failed both medical interventions and surgical sphincter repair.

Sacral nerve stimulation (sacral neuromodulation) is covered via a two-stage process for members with chronic fecal incontinence who have had an inadequate response to conservative treatments and who have a weak but structurally intact anal sphincter. First, a temporary percutaneous peripheral nerve electrode (CPT 64561) must be placed. Then, if the member achieves 50% or greater improvement in incontinence symptoms over at least 48 hours of testing, implantation of a permanent pulse generator (CPT 64590) is covered. Aetna notes this can be administered via InterStim. CPT 64581 — the open incisional approach to electrode lead implantation — is the surgical alternative to percutaneous placement via CPT 64561. Both are covered when selection criteria are met. The HCPCS codes for the hardware — C1767, C1778, C1787, C1820, L8679, L8680, L8685, L8686, L8687, L8688 — all fall under the same criteria gate. If the temporary trial doesn't meet the 50% threshold, the permanent implant is considered experimental.

The reimbursement path for sacral neuromodulation is clear, but it's also sequential. Don't bill for the permanent generator (CPT 64590) before you have documentation showing the temporary trial result. That's a clean denial waiting to happen.

---

Aetna Fecal Incontinence Exclusions and Non-Covered Indications

This section is where fecal incontinence billing gets expensive if your team isn't paying attention. Aetna's list of experimental, investigational, or unproven designations is long — and several of these codes are in active use at many practices.

Injectable bulking agents are explicitly experimental. That means CPT 11950, 11951, 11952, 11953, 11954 (subcutaneous injection of filling material) and CPT 0963T (anoscopy with directed submucosal injection of bulking agent) are not covered for fecal incontinence under this policy. HCPCS L8605 (dextranomer/hyaluronic acid copolymer implant) is also in the non-covered group. If you've been billing these, stop — or expect denials.

Posterior tibial nerve stimulation (CPT 64566) is also in the experimental bucket. Some practices use this as an alternative neuromodulation approach. Aetna does not cover it for fecal incontinence under CPB 0611.

Graciloplasty is experimental. So are anal slings, pubo-rectal slings, and the Fenix Continence Restoration System. HCPCS A4563 (rectal control system for vaginal insertion) sits in the same non-covered group.

Autologous muscle cell therapy — CPT 1001T — is also experimental. Same for mesenchymal stem cell injections. The codes 38205, 38206, 38240, and 38241 (hematopoietic progenitor cell harvesting and transplantation) appear in the experimental group as well.

Category III codes 0587T, 0588T, 0589T, and 0590T — covering integrated single-device neurostimulation systems — are non-covered under this policy. These are newer technology codes. Aetna is not convinced yet.

The Acticon Neosphincter is also non-covered if the member has any of these contraindications: an irreversibly obstructed proximal bowel segment, or being a poor candidate for surgery or anesthesia due to physical or mental conditions. Even if all other criteria are met, these contraindications flip the coverage status.

---

Coverage Indications at a Glance

---

Aetna Fecal Incontinence Billing Guidelines and Action Items 2026

This update has real claim denial risk if your charge capture and documentation workflows don't reflect the current criteria. Here's what to do before billing under CPB 0611.

Copy Action Items

If you're unsure how this coverage policy applies to your specific payer mix or plan types, talk to your compliance officer before the effective date of February 27, 2026.

---

CPT, HCPCS, and ICD-10 Codes for Fecal Incontinence Under CPB 0611

Covered CPT Codes (When Selection Criteria Are Met)

Other CPT Codes Related to CPB 0611

Not Covered / Experimental CPT Codes

Covered HCPCS Codes (When Selection Criteria Are Met)

Not Covered / Experimental HCPCS Codes

Code	Type	Description	Reason Copy
A4563	HCPCS	Rectal control system for vaginal insertion, for long term use	Experimental — anal sling / Fenix system
L8605	HCPCS	Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, anal canal, 1 ml	Experimental — injectable bulking agents

Other HCPCS Codes Related to CPB 0611

Key ICD-10-CM Diagnosis Codes

---